JAAM
The Joint Access Advisory Mechanism
The Joint Access Advisory Mechanism (JAAM) is the entryway for the European COVID-19 adaptive platform trials (APTs). It is the single body, common to the EU-SolidAct, REMAP-CAP and ECRAID Prime trials, that assesses requests from investigators or industry looking to test their compound in one or more of these trials.
Composition
The JAAM is composed of a panel of seven renowned experts that are fully independent from the EU-funded APTs. They cover the following fields of expertise:
- Pre-clinical research, animal models and basic virology
- Clinical virology and infectious diseases
- Immunology and inflammation
- Pharmacology
- Trial methodology
- Health technology assessment
The coordinators of the EU RESPONSE and RECOVER projects, and the principal investigators of the EU-SolidAct, REMAP-CAP in Europe and ECRAID Prime trials are observers of the JAAM.
How it works
The JAAM meets regularly, to assess requests for access according to the following criteria :
1- Public health interest;
2- Scientific, medical and ethical soundness;
3- Appropriate patient population, comparator and outcomes;
4- Promotion of coordination and optimal use of resources.
Download the JAAM brochure
Process and timelines
The applicant must first submit their proposal directly to the JAAM Secretariat at covid19trialseu@ecrin.org. Applicants will be requested to cover all key characteristics of the compound. The JAAM Secretariat will then ensure all information provided by the applicant is complete (and may request additional information), and will consult the JAAM chair for eligibility of the compound.
Assessment process of the JAAM: